Private Equity

Private equity firm Astara Capital Partners hires a top talent chief, signaling a strategic shift from financial engineering to human-led operational growth.

PatientPoint founder Mike Collette joins Carefeed's board, signaling a major push to tackle senior living's operational crises with proven tech leadership.

A new Edmonton health centre embeds pharmacy services directly into patient care, aiming to fix a fragmented system and empower local pharmacists.

Easterly Asset Management's deal to absorb Olstein's funds marks a key industry consolidation, promising lower fees and a unified value investing powerhouse.

The private equity firm hires Laura Noisten to lead leveraged finance, a strategic move to fuel growth in the complex aerospace and defense tech sector.

PainTEQ's landmark deal, crowned 'Deal of the Year,' showcases a new model for medtech growth and its patient-first mission in pain management.

Risk Theory's first MGA acquisition of Roundhill Express signals a new buy-and-build era, targeting the high-stakes NYC specialty property market.

REPKON USA rebrands as Paligen, signaling a new era of domestic defense manufacturing fueled by a landmark TNT contract and strategic acquisitions.

After its Alzheimer's drug failed amidst controversy, Cassava Sciences rebrands as Filana Therapeutics, betting its future on a rare epilepsy disorder.

In a tough PE climate, Truelink Capital rapidly closes its second fund at its $2B hard cap, signaling strong investor belief in its operational strategy.

VLS Environmental Solutions expands its hazardous waste network by acquiring California-based IDR, a strategic move in a highly regulated market.

An Austin startup is launching an intelligence platform to help marketing leaders see a company's red flags before accepting a misaligned leadership role.

Praesidian Capital unites iconic model train maker Lionel with hobby giant Round 2, creating a new collectibles empire focused on innovation and growth.

Agenus activates a key manufacturing pact with Zydus, scaling production for its promising BOT+BAL cancer therapy ahead of regulatory filings and market launch.

With its CAR-T therapy achieving franchise profitability and treating 10,000 patients, Legend Biotech eyes overall profit and next-gen cancer treatments.

Celebrating 80 years, Aveeno renews its foundational ties with Mayo Clinic, launching a new era of oat science research for compromised skin.

Uranium Energy Corp reports a strong quarter with new mine completion, robust finances, and a strategic push to build a fully domestic nuclear fuel cycle.

Copenhagen Infrastructure Partners' new credit fund highlights soaring investor demand for green debt, aiming to accelerate the energy transition worldwide.

A new partnership aims to deploy over a billion dollars into restoring global ecosystems, betting on high-integrity carbon credits to fund the fight for nature.

OSE Immunotherapeutics confirms Marc Le Bozec as CEO, betting on his turnaround expertise to navigate market pressures and commercialize its key therapies.